Papain-like protease (PLpro) is a promising therapeutic target against SARS-CoV-2, but its
restricted S1/S2 subsites pose an obstacle in developing active site-directed inhibitors. We …

In the global fight against the COVID-19 pandemic caused by the highly transmissible SARS-
CoV-2 virus, the search for potent medications is paramount. With a focused investigation on …

Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with very limited treatments so far …

The COVID-19 disease has infected and killed countless people all over the world since its
emergence at the end of 2019. No specific therapy for COVID-19 is not currently available …

The main protease (Mpro) is a key enzyme responsible for severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) replication that causes the spread of the global …

Abstract SARS-CoV-2's papain-like protease (PLpro) interaction with ligands has recently
been explored with a myriad of crystal structures. We used molecular dynamics (MD) …

The SARS-CoV-2 papain-like protease (PLpro) is an antiviral drug target that catalyzes the
hydrolysis of the viral polyproteins pp1a/1ab, so releasing the non-structural proteins (nsps) …

Coronaviruses such as SARS-CoV-2 encode a conserved papain-like protease (PLpro) that
is crucial for viral replication and immune evasion, making it a prime target for antiviral drug …

Inhibition of the papain-like protease (PLpro) of SARS-CoV-2 has been demonstrated to be
a successful target to prevent the spreading of the coronavirus in the infected body. In this …

To date, mechanistic insights into many clinical drugs against COVID-19 remain unexplored.
Dexamethasone, a corticosteroid, is one of them. While treating the entire corticosteroid …